The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies. During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients. Each year, there is one key conference dedicated to bringing these stakeholders together with the sole goal of discussing the development of

Targeted therapies, or treatments directed towards specific biomarkers in tumor cells, have been effective in treating many patients with advanced-stage non-small cell lung cancer (NSCLC). Tumors that have the ALK protein fused with another cancer-driving protein, such as the EML4 protein, are often referred to as ALK-positive tumors. Approximately 5% of advanced-stage adenocarcinoma, a type of NSCLC, will test positive for an ALK-fusion biomarker. Treating patients with ALK-positive lung cancer with a class of drugs called tyrosine kinase inhibitors (TKIs) has been an effective approach

Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Triparna Sen, PhD, as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC, including EGFR, ALK, and RET. This Facebook Live event is hosted by Amy Moore, PhD, LUNGevity’s Vice President of Global Engagements and Patient Partnerships. Dr. Sen is Co-Director of the Lung Cancer PDX Platform at the Center for Thoracic Oncology, Icahn School of Medicine at

LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director of Research, interviewed Hilary Hammell (RETpositive) and Dr. Alexandre Reuben (MD Anderson Cancer Center) about an exciting project on using the immune system to treat RET-positive lung cancer. This project is being funded by the RETpositive patient group. This interview was live on Facebook on October 18; watch the video here.

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.

The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in person to make this year’s meeting one of the largest gatherings since the start of the pandemic. They shared the many exciting developments in cancer research and treatment that emerged over the last year. This year’s meeting is another testament to “Science doesn’t stop, and scientists never sleep!” Here, we discuss some of the major highlights of the meeting. Cancer Interception and Early Detection: A major theme at